

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Binding Studies of Eukaryotic Initiation Factor eIF4E with Novel mRNA Dinucleotide Cap Analogues

Joanna Zuberek<sup>a</sup>; Jacek Jemielity<sup>a</sup>; Janusz Stepinski<sup>a</sup>; Magdalena Lewdorowicz<sup>a</sup>; Anna Niedzwiecka<sup>a</sup>; Dorota Haber<sup>a</sup>; Ryszard Stolarski<sup>a</sup>; Robert E. Rhoads<sup>b</sup>; Edward Darzynkiewicz<sup>a</sup>

<sup>a</sup> Department of Biophysics, Institute of Experimental Physics, Warsaw University, Warszawa, Poland <sup>b</sup>

Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA

Online publication date: 09 August 2003

**To cite this Article** Zuberek, Joanna , Jemielity, Jacek , Stepinski, Janusz , Lewdorowicz, Magdalena , Niedzwiecka, Anna , Haber, Dorota , Stolarski, Ryszard , Rhoads, Robert E. and Darzynkiewicz, Edward(2003) 'Binding Studies of Eukaryotic Initiation Factor eIF4E with Novel mRNA Dinucleotide Cap Analogues', *Nucleosides, Nucleotides and Nucleic Acids*, 22: 5, 1703 — 1706

**To link to this Article:** DOI: 10.1081/NCN-120023118

**URL:** <http://dx.doi.org/10.1081/NCN-120023118>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Binding Studies of Eukaryotic Initiation Factor eIF4E with Novel mRNA Dinucleotide Cap Analogues

Joanna Zuberek,<sup>1</sup> Jacek Jemielity,<sup>1</sup> Janusz Stepinski,<sup>1</sup>  
Magdalena Lewdorowicz,<sup>1</sup> Anna Niedzwiecka,<sup>1</sup>  
Dorota Haber,<sup>1</sup> Ryszard Stolarski,<sup>1</sup> Robert E. Rhoads,<sup>2</sup>  
and Edward Darzynkiewicz<sup>1,\*</sup>

<sup>1</sup>Department of Biophysics, Institute of Experimental Physics,  
Warsaw University, Warszawa, Poland

<sup>2</sup>Department of Biochemistry and Molecular Biology, Louisiana State University  
Health Sciences Center, Shreveport, Louisiana, USA

### ABSTRACT

Studies on the interaction of the murine translation initiation factor 4E with two new-synthesized cap-analogues, modified at C2' of 7-methylguanosine, have been performed by means of the fluorescence titration method. No difference in the binding affinity for eIF4E was observed compared with the “anti reversed” cap analogues, possessing the analogous modifications at C3'. Potential significance of the novel caps as research tools for examination of the nuclear cap binding complex CBC80/20 has been discussed.

\*Correspondence: Edward Darzynkiewicz, Department of Biophysics, Institute of Experimental Physics, Warsaw University, Zwirki i Wigury 93, 02-089 Warszawa, Poland; Fax: + 48 22 654 0001; E-mail: edek@biogeo.uw.edu.pl.




## INTRODUCTION

The 5' mRNA cap structure  $m^7G(5')ppp(5')N$ , which consists of 7-methylguanosine linked via a 5'-to-5' triphosphate bridge to the first transcribed nucleotide N, plays a crucial role in many cellular processes, such as splicing of pre-mRNA, intracellular RNA export to cytoplasm, and facilitation of the cap-dependent translation. For that reason, the ability to synthesise capped mRNA transcripts in vitro constitutes a useful research tool. The most frequently employed technique is to transcribe a DNA template with bacteriophage RNA polymerase in the presence of all four ribonucleotide triphosphates and a dinucleotide cap analogue,  $m^7GpppG$ .<sup>[3,4]</sup> However, it was found that 30–50% of the  $m^7GpppG$  is incorporated in the reverse orientation,<sup>[5]</sup> i.e., with the  $m^7Guo$  moiety linked by a 3'-5' phosphodiester bond to the mRNA chain. Recently, two novel Anti-Reverse Cap Analogues (ARCAs) have been synthesised,<sup>[6]</sup> in which 3'OH of  $m^7G$  was either replaced by 3'OCH<sub>3</sub> or changed to 3'deoxy. The modifications protect against incorporation of cap in the reverse orientation to the mRNA transcripts. It was shown that the ARCA-capped transcripts are translationally more active than the traditional ones.<sup>[6]</sup>

## RESULTS AND DISCUSSION

The recognition of the 5' mRNA cap by one of the components of the translation machinery, i.e., the eIF4E factor, is a crucial, rate-limiting step in initiation of protein synthesis.<sup>[1]</sup> To compare the binding affinity of eIF4E for the ARCAs and for the novel cap-analogues, possessing these same modifications at C2' in  $m^7G$  we have determined the association constants  $K_{as}$  for the eIF4E-cap complexes (Fig. 1 and Table 1) by means of the fluorescence quenching method.<sup>[7]</sup>


The values of the association constants ( $K_{as}$ ) for both classes of the tested cap analogues:  $m^73'dGpppG$ ,  $m_2^{7,3'O}GpppG$ ,  $m^72'dGpppG$ , and  $m_2^{7,2'O}GpppG$  as well



**Figure 1.** Fluorescence titration curves for binding of the Anti-Reverse Cap Analogues to eIF4E. Comparison of the analogues modified at C2' and C3' of  $m^7G$  with  $m^7GpppG$ , left and right panels, respectively. The titrations were performed in 50 mM HEPES/KOH pH 7.2, 0.1 M KCl, 0.5 mM EDTA, 1 mM DTT, at 20°C, by adding 1  $\mu$ L of the cap analogue solution to 1400  $\mu$ L of 0.1  $\mu$ M eIF4E(28–217).

**Table 1.** The values of  $K_{as}$  for the association of murine eIF4E(28–217) with the dinucleoside triphosphate cap analogues.

Cap analogues	$K_{as}$ ( $\mu\text{M}^{-1}$ )
$m^7\text{GpppG}$	$12.5 \pm 0.3$
$m_2^{7,2'}\text{O GpppG}$	$10.8 \pm 0.3$
$m^{7,2'}\text{dGpppG}$	$9.1 \pm 0.5$
$m_2^{7,3'}\text{O GpppG}$	$10.2 \pm 0.3$
$m^{7,3'}\text{dGpppG}$	$13.1 \pm 0.7$



as the parent  $m^7\text{GpppG}$ , are very similar (Table 1). The observed differences are within 20%;  $K_{as} = 9.1 \pm 0.5 \cdot 10^6 \text{ M}^{-1}$  for  $m^{7,2'}\text{dGpppG}$  and  $K_{as} = 12.5 \pm 0.3 \cdot 10^6 \text{ M}^{-1}$  for  $m^7\text{GpppG}$ . The results are consistent with the crystallographic study of the murine eIF4E- $m^7\text{GDP}$  complex,<sup>[8]</sup> which showed that C2' and C3' do not interact directly with the protein and are located outside the protein surface.

Since the modifications at the C3' or C2' of  $m^7\text{Guo}$  do not affect the eIF4E-cap interaction, the mRNA transcripts capped with novel "ARCs" could be more effective templates for protein synthesis. Moreover, the novel cap analogues are very useful for studying the interactions with the Nuclear Cap Binding Complex.<sup>[9]</sup> This functional hetero-dimer, consisting of a small, CBC20, and a large, CBC80 subunits, binds with high affinity to the 5' cap of nascent RNA polymerase II transcripts, and on the contrary to eIF4E, CBC20 forms three direct hydrogen bonds with the 2'- and 3'-hydroxyl groups of  $m^7\text{G}$ .<sup>[10]</sup> The novel analogues are therefore a good tool to probe the contribution of the  $m^7\text{G}$  ribose ring to the stabilization energy in the CBC-cap complex.

## ACKNOWLEDGMENT

This work was supported by KBN 6 P04A 055 17, PBZ-KBN 059/T09/10, BST-718/BF, BW-1525/BF.

## REFERENCES

1. Mathews, M.B.; Sonenberg, N.; Hershey, J.W.B. In *Translational Control of Gene Expression*; Sonenberg, N., Hershey, J.W.B., Mathews, M.B., Eds.; CSHL Press, 2000; 1–32.
2. Furuichi, Y.; Shatkin, A.J. *Adv. Virus Res.* **2000**, *55*, 135–184.
3. Konarska, M.M.; Padgett, R.A.; Sharp, P.A. *Cell* **1984**, *38*, 731–736.
4. Yisraeli, J.K.; Melton, D.A. *Methods Enzymol.* **1989**, *180*, 42–50.
5. Pasquinelii, A.E.; Dahlberg, J.E.; Lund, E. *RNA* **1995**, *1*, 957–967.
6. Stepinski, J.; Waddell, C.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R.E. *RNA* **2001**, *7*, 1486–1495.

7. Niedzwiecka, A.; Marcotrigiano, J.; Stepinski, J.; Jankowska-Anyszka, M.; Wyslouch-Cieszyńska, A.; Dadlez, M.; Gingras, A.C.; Mak, P.; Darzynkiewicz, E.; Sonenberg, N.; Burley, S.K.; Stolarski, R. *J. Mol. Biol.* **2002**, *319*, 615–6358.
8. Marcotrigiano, J.; Gingras, A.C.; Sonenberg, N.; Burley, S.K. *Cell* **1997**, *89*, 951–961.
9. Lewis, J.D.; Izaurralde, E. *Nucl. Acid Res.* **1997**, *24*, 3332–3336.
10. Mazza, C.; Segref, A.; Mattaj, I.W.; Cusack, S. *EMBO J.* **2002**, *21*, 5548–5557.

